The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial

The Myeloma X trial (ISCRTN60123120) registered patients with relapsed multiple myeloma. Participants were randomised between salvage autologous stem cell transplantation (ASCT) or weekly cyclophosphamide following re‐induction therapy. Cytogenetic analysis performed at trial registration defined t(...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Cook, Gordon, Royle, Kara‐Louise, O'Connor, Sheila, Cairns, David A., Ashcroft, A. John, Williams, Cathy D., Hockaday, Anna, Cavenagh, Jamie D., Snowden, John A., Ademokun, Debo, Tholouli, Eleni, Andrews, Vivienne E., Jenner, Matthew, Parrish, Christopher, Yong, Kwee, Cavet, Jim, Hunter, Hannah, Bird, Jenny M., Pratt, Guy, Drayson, Mark T., Brown, Julia M., Morris, Treen C. M.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Haematological Malignancy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6519200/
https://ncbi.nlm.nih.gov/pubmed/30729512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15782
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados